NDRA stock icon

ENDRA Life Sciences

5.33 USD
-0.14
2.56%
Updated Dec 3, 9:37 AM EST
1 day
-2.56%
5 days
-4.48%
1 month
-40.71%
3 months
-56.24%
6 months
-98.60%
Year to date
-99.81%
1 year
-99.75%
5 years
-99.98%
10 years
-100.00%
0
Funds holding %
of 6,780 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

0.22% less ownership

Funds ownership: 1.15% [Q2] → 0.93% (-0.22%) [Q3]

33% less funds holding

Funds holding: 15 [Q2] → 10 (-5) [Q3]

56% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 9

78% less capital invested

Capital invested by funds: $78.7K [Q2] → $17K (-$61.8K) [Q3]

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 6

Research analyst outlook

We haven’t received any recent analyst ratings for NDRA.

Financial journalist opinion

Based on 4 articles about NDRA published over the past 30 days

Neutral
Business Wire
1 week ago
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it has regained compliance with the minimum bid price requirement set forth by The Nasdaq Stock Market LLC (“Nasdaq”). On November 21, 2024, the Company received notification from the Nasdaq Listing Qualifications Department confirming its compliance with Listing Rule 5550(a)(2), thereby meeting Nasdaq's maintenance requirements for listi.
ENDRA Life Sciences Regains Compliance with Nasdaq Minimum Bid Price Requirement
Neutral
Business Wire
2 weeks ago
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2024 and provided a business update. Highlights from the third quarter and recent weeks include: Developed data analysis features for TAEUS platform by introducing new models rooted in artificial intelligence (AI), machine learning (ML) and deep learning (DL). As part of its conti.
ENDRA Life Sciences Reports Third Quarter 2024 Financial Results and Provides a Business Update
Neutral
Business Wire
3 weeks ago
Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), an innovator of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced the acceptance of a poster titled “Noninvasive assessment of steatotic liver disease in individuals with class 2 and class 3 obesity” for presentation at The Liver Meeting 2024, hosted by the American Association for the Study of Liver Disease (AASLD), taking place November 15-19 in San Diego. “This presentation highlights the potential of our.
Study Highlighting ENDRA Life Sciences' TAEUS Technology in Patients with High BMI to be Presented at AASLD's The Liver Meeting® 2024
Neutral
Business Wire
3 weeks ago
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued to ENDRA a new patent EP4247282 (the ‘282 patent) titled “Method and System for Monitoring Tissue Temperature.” The ‘282 patent relates to a novel method and system for monitoring tissue ablation during minimally invasive thermal surgical interventions by utilizing ENDRA's TAEUS® system. It is related to ENDRA.
ENDRA Life Sciences Further Strengthens TAEUS® Platform Intellectual Property with Issuance of 17th European Patent
Neutral
Business Wire
1 month ago
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
ANN ARBOR, Mich.--(BUSINESS WIRE)--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the activation of a post market clinical study and first patient scanned with the TAEUS liver system at LMU University Hospital in Munich, one of the leading medical research centers in Europe. LMU University Hospital is conducting a post market clinical study to collect data to assess TAEUS' liver fat measurement capabilities against the gold standard.
ENDRA Life Sciences Activates TAEUS System to Initiate Clinical Study at LMU University Hospital in Germany
Positive
Benzinga
3 months ago
Data I/O And 2 Other Stocks Under $5 Executives Are Buying
The Dow Jones index closed higher by more than 200 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects.
Data I/O And 2 Other Stocks Under $5 Executives Are Buying
Neutral
Business Wire
3 months ago
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that on August 27, 2024, the Company was notified by The Nasdaq Stock Market LLC (“Nasdaq”) that the Nasdaq Hearings Panel (the “Panel”) has granted the Company's request for an extension through November 20, 2024, to evidence compliance with the $1.00 bid price requirement for continued listing on The Nasdaq Capital Market. To regain compliance.
ENDRA Life Sciences Granted Extension to Regain Compliance with Nasdaq Continued Listing Requirements
Neutral
Seeking Alpha
3 months ago
ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript
ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2024 Earnings Conference Call August 22, 2024 4:30 PM ET Company Participants Yvonne Briggs - LHA Investor Relations Alexander Tokman - Acting CEO Ziad Rouag - Head of Regulatory and Clinical Affairs Michael Thornton - Chief Technology Officer Richard Jacroux - CFO Conference Call Participants Edward Woo - Ascendiant Capital Operator Good afternoon, and welcome to the ENDRA Life Sciences Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
ENDRA Life Sciences Inc. (NDRA) Q2 2024 Earnings Call Transcript
Neutral
Business Wire
3 months ago
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), reports financial results for the three and six months ended June 30, 2024, as filed in a Form 10-Q on August 14, 2024, and provides the following business update: New executive team Subsequent to quarter-end, ENDRA announced leadership changes. Board member Alexander Tokman was appointed as acting CEO, bringing 24+ years of global commercial leadership experien.
ENDRA Life Sciences Reports Second Quarter 2024 Financial Results and Provides a Business Update
Neutral
Business Wire
3 months ago
ENDRA Life Sciences Announces Reverse Stock Split
ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (“ENDRA”) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that it will implement a 1-for-50 reverse stock split of the issued shares of its common stock (the “Reverse Stock Split”), effective at 12:01 a.m. Eastern time on August 20, 2024. The Company's common stock is expected to begin trading on a split-adjusted basis when the market opens on Tuesday, August 20, 2024, and will continue to tra.
ENDRA Life Sciences Announces Reverse Stock Split
Charts implemented using Lightweight Charts™